First Bank & Trust Has $90,000 Position in MEDNAX Inc (MD)

First Bank & Trust increased its stake in MEDNAX Inc (NYSE:MD) by 18.7% in the first quarter, Holdings Channel reports. The institutional investor owned 3,334 shares of the company’s stock after acquiring an additional 526 shares during the period. First Bank & Trust’s holdings in MEDNAX were worth $90,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in MD. Oregon Public Employees Retirement Fund increased its stake in MEDNAX by 3,200.0% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 1,223,145 shares of the company’s stock worth $37,000 after purchasing an additional 1,186,080 shares during the period. Bremer Trust National Association purchased a new stake in MEDNAX in the fourth quarter worth $44,000. First Mercantile Trust Co. increased its stake in MEDNAX by 13.8% in the fourth quarter. First Mercantile Trust Co. now owns 2,275 shares of the company’s stock worth $76,000 after purchasing an additional 275 shares during the period. ETF Managers Group LLC increased its stake in MEDNAX by 18.8% in the fourth quarter. ETF Managers Group LLC now owns 2,404 shares of the company’s stock worth $79,000 after purchasing an additional 381 shares during the period. Finally, Ffcm LLC increased its stake in MEDNAX by 137.0% in the fourth quarter. Ffcm LLC now owns 3,155 shares of the company’s stock worth $104,000 after purchasing an additional 1,824 shares during the period. Institutional investors and hedge funds own 94.98% of the company’s stock.

MD has been the topic of a number of recent analyst reports. Mizuho set a $36.00 target price on MEDNAX and gave the stock a “hold” rating in a research note on Friday, February 8th. Zacks Investment Research lowered MEDNAX from a “hold” rating to a “sell” rating in a research note on Wednesday, February 6th. Credit Suisse Group reduced their target price on MEDNAX from $44.00 to $42.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 13th. Citigroup upgraded MEDNAX from a “neutral” rating to a “buy” rating and set a $34.88 target price on the stock in a research note on Monday, January 14th. They noted that the move was a valuation call. Finally, Deutsche Bank initiated coverage on MEDNAX in a research note on Thursday, January 3rd. They issued a “hold” rating and a $34.00 target price on the stock. Three investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $40.44.

Shares of MEDNAX stock opened at $26.66 on Wednesday. The firm has a market cap of $2.42 billion, a PE ratio of 7.60, a PEG ratio of 1.01 and a beta of 0.58. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.31 and a current ratio of 1.31. MEDNAX Inc has a 12 month low of $26.60 and a 12 month high of $53.17.

MEDNAX (NYSE:MD) last announced its quarterly earnings results on Thursday, February 7th. The company reported $0.92 EPS for the quarter, beating the consensus estimate of $0.83 by $0.09. The firm had revenue of $932.70 million for the quarter, compared to analyst estimates of $910.08 million. MEDNAX had a return on equity of 10.35% and a net margin of 7.37%. The business’s revenue for the quarter was up 2.4% on a year-over-year basis. During the same quarter last year, the firm posted $0.87 earnings per share. Sell-side analysts predict that MEDNAX Inc will post 3.43 earnings per share for the current year.

In other news, SVP Dominic J. Andreano sold 1,289 shares of the firm’s stock in a transaction on Wednesday, February 20th. The stock was sold at an average price of $36.22, for a total transaction of $46,687.58. Following the transaction, the senior vice president now owns 69,069 shares in the company, valued at $2,501,679.18. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider John C. Pepia sold 2,500 shares of the firm’s stock in a transaction on Tuesday, January 22nd. The shares were sold at an average price of $36.60, for a total value of $91,500.00. Following the transaction, the insider now owns 28,583 shares in the company, valued at approximately $1,046,137.80. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 30,279 shares of company stock worth $988,954. Insiders own 3.40% of the company’s stock.

WARNING: This story was originally posted by Markets Daily and is the property of of Markets Daily. If you are viewing this story on another domain, it was illegally stolen and republished in violation of United States and international trademark & copyright law. The correct version of this story can be viewed at https://www.themarketsdaily.com/2019/04/17/first-bank-trust-has-90000-position-in-mednax-inc-md.html.

MEDNAX Profile

MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology and teleradiology, pediatric cardiology, and other pediatric subspecialty physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care services; and acute and chronic pain management services.

Featured Article: Trading Options- What is a Strangle?

Want to see what other hedge funds are holding MD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MEDNAX Inc (NYSE:MD).

Institutional Ownership by Quarter for MEDNAX (NYSE:MD)

Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.